ABIONYX Pharma SA (FR:ABNX)
:ABNX
Want to see FR:ABNX full AI Analyst Report?
ABNX Stock Chart & Stats
€3.70
>-€0.01(-0.63%)
At close: 4:00 PM EST
€3.70
>-€0.01(-0.63%)
Day’s Range― - ―
52-Week Range€1.17 - €5.29
Previous CloseN/A
Volume9.43K
Average Volume (3M)284.77K
Market Cap
€124.53M
Enterprise Value€124.92M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding35,511,654
10 Day Avg. Volume172,880
30 Day Avg. Volume284,772
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Specialized R&D FocusABIONYX’s concentrated scientific focus on recombinant apoA‑I constitutes a durable strategic asset: it creates a clear platform expertise applicable across inflammatory, infectious and severe disease indications, supporting differentiated clinical value and potential licensing or partnership leverage over time.
Positive Equity / SolvencyDespite erosion, reported positive equity indicates the company remains solvent and able to continue operations without immediate default risk. That balance‑sheet cushion provides time to advance clinical programs or structure financings, a materially better position than insolvent peers in a capital‑intensive biotech sector.
Operating Cash Burn ImprovingReduced operating cash outflow year‑over‑year suggests management is making progress on cost control or revenue generation. A sustained decline in cash burn improves runway and lowers near‑term financing frequency, increasing the probability the company can reach clinical inflection points that attract non‑dilutive funding or partnerships.
Bears Say
Persistent Negative Cash GenerationContinued operating and free cash outflows are a structural risk: sustained negative cash generation necessitates recurrent external financing, likely dilutive equity raises or debt that elevates cost of capital. Over multiple quarters this undermines shareholder value and constrains long‑term program funding unless offset by a material revenue or partnership event.
Rising LeverageA near doubling of debt-to-equity in one year reduces financial flexibility and raises refinancing risk if clinical or commercial timelines slip. Higher leverage increases interest and covenant pressure, narrows strategic options, and can force unfavorable financing terms that dilute or constrain long‑term R&D investment.
Weak Profitability And MarginsSharply deteriorating gross margin and deeply negative EBIT margin point to a structurally unprofitable operating model at current scale. Without clear pathway to durable margin expansion—through pricing, scale or cost base change—the company will remain dependent on external capital and vulnerable to funding shortfalls as clinical programs advance.
ABNX FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest stock price was €1.17 and its highest was €5.29 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €124.53M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 126 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.092 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.092.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 35,511,654 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.448%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in FR:ABNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.